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To determine the outcome of kidney transplantation in
patients with fibrillary glomerulonephritis (FGN), a rare
glomerular disease, we followed 12 patients, 5 with FGN and
7 patients with monoclonal gammopathy and fibrillary
deposits (MGFD), who underwent 15 kidney transplants since
1988 with a median follow-up of 52 months. Recurrent
disease did not arise in any of the patients with FGN but
developed in 5 patients with MGFD. Seven allografts failed: 1
in the FGN group and 6 in the MGFD group. Median allograft
survival for patients with MGFD was 37 months but had not
been reached in FGN patients. One patient with FGN had
primary allograft failure secondary to graft
thromboembolism. Three patients with MGFD were re-
transplanted and one lost the second allograft to recurrent
disease, but the other two died from hematological
malignancy. Another patient was diagnosed with MPGN type
III and did not have detectable fibrillary material 22 months
after transplantation. One patient with MGFD had stable
allograft function 6 months post-transplant but another, with
recurrent disease, underwent peripheral blood stem cell
transplantation and regained stable allograft function. Our
study shows that kidney transplantation appears safe in
patients with FGN with little risk of recurrence. However,
patients with MGFD have a significant risk for disease
recurrence. Whether the development of hematological
malignancies following transplantation in this group is
related to their original disease or was coincidental requires
further studies.
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Fibrillary glomerulonephritis (FGN) is a rare disorder
comprising 0.6–1.5% of native kidney biopsies.1–5 The disease
is characterized by the deposition of fibrillary structures in
glomeruli that range from 16 to 24 nm in diameter.1,5–8
Immunofluorescence (IF) usually shows bright diffuse
glomerular staining for immunoglobulin (Ig) G and C3,
with more variable and weaker positivity for other im-
munoglobulins.1 By definition, the fibrils are Congo red or
thioflavin T negative, a biochemical characteristic that
distinguishes them from amyloid fibrils. Some have proposed
that the fibrils in patients with FGN should be p30 nm in
diameter and randomly arranged.5,9,10 This is in contrast to
immunotactoid glomerulopathy where the fibrils (or micro-
tubules) are focally organized into parallel bundles and are
X30 nm in diameter. Although it has been suggested that
FGN is less frequently associated with lymphoplasmacytic
disorders than IT, a number of publications have included
patients with lymphoproliferative and myeloproliferative
disorder, as well as patients with circulating monoclonal
proteins as part of the group defined as having FGN.4–6,11
However, other authors suggest that the term FGN should be
reserved for cases where secondary causes have been
excluded.12
Clinically, FGN manifests with proteinuria, hematuria,
and hypertension with progression to end-stage renal disease
(ESRD) occurring within the course of months to a few
years.1,4,5,7,12,13 Various therapeutic approaches, including
corticosteroids, cytotoxic agents, cyclosporin A, and plasma-
pheresis have been attempted in patients with FGN without
clear beneficial results with ESRD developing within 2–4 years
in about half of the patients.1,4,5 This poor therapeutic
response may be because of the advanced degree of renal
damage present at diagnosis in the majority of cases.4
Kidney transplantation (KTX) has been performed in
patients with ESRD secondary to FGN and IT glomerulo-
pathy, but with the exception of a few reports documenting
post-transplant recurrence, little is known about the long-
term outcome of KTX in patients with FGN.6,14–16 The most
comprehensive study so far was published by Samaniego
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et al.17 who reviewed the outcome of 4 patients transplanted
at their institution and 10 additional cases taken from the
literature. In this report, which combines the published world
experience with KTX in patients with FGN, the recurrence
rate was high (B50%), but recurrence was associated with a
relatively benign course and prolonged graft survival was
possible.17 The paucity of information regarding transplanta-
tion outcomes for FGN led us to review the outcome of
patients with FGN who had received KTX at our center
during the past two decades. In this process, we came across a
number of patients who had been labeled as having ESRD
secondary to FGN, but in addition to the fibrillary deposits
observed on kidney biopsies, these patients also had a
monoclonal gammopathy documented. Fibrillary glomerular
deposits have been described in patients with monoclonal
gammopathies.18–21 In some cases, the linear immunoglobu-
lin staining seen on IF reflects that of the circulating
monoclonal protein and occur in the same distribution as
is seen by electron microscopy (EM), thus suggesting a link
between the circulating monoclonal protein and the renal
pathology.14
We present the clinical characteristics, pathologic findings,
and the long-term outcome of 15 KTX episodes in 12 patients
(GFN¼ 5; monoclonal gammopathy and fibrillary deposit,
MGFD¼ 7) transplanted at our institution since 1988. To
our knowledge, this represents the largest single-center case
series of KTX in patient with fibrillary deposits, and provides
further information on the natural history and rate of disease
recurrence post-KTX in these two groups of patients.
METHODS
Study population
All KTX carried out at Mayo Clinic between January 1988 and
December 2007 were reviewed. FGN was defined according to
Rosenstock et al.4 where the fibrils should be (1) randomly oriented;
(2) lacked hollow centers at magnifications of o 30,000;
(3) measure o30 nm in diameter; (4) Congo red-negative; and
(5) stained with antisera to immunoglobulins by routine IF. The
same criteria were used to establish FGN in the allograft. Biopsies
with a clinicopathologic diagnosis of amyloidosis, cryoglobulinemic
glomerulonephritis, or lupus nephritis were excluded. To avoid
confusion and better our understanding of FGN and the course of
renal transplantation, patients were divided into two groups: (1)
patients with FGN and (2) patients with MGFDs. Monoclonal
gammopathy was defined as a detectable monoclonal protein in the
serum and/or urine. Allografts were biopsied as per protocol or as
indicated by a decline in renal function or an increase in proteinuria.
Renal biopsies were processed for light microscopy and IF and
recurrences were confirmed by electron microscopic examination of
the allograft biopsy. Pertinent clinical and laboratory data and
information on KTX, treatment and follow-up were extracted from
patient records. All patients had authorized the use of their medical
records for research in accordance with Minnesota privacy statues,
and the study was approved by the Institutional Review Board at the
Mayo Foundation in accordance with the Declaration of Helsinki
and the Health Insurance Portability and Accountability Act
guidelines. Time to ESRD was calculated from time of diagnosis
to either initiation of dialysis or KTX. Allograft survival and
recurrence rates were calculated using Kaplan–Meier method. Group
comparisons for the time of diagnosis to time to ESRD or KTX were
made using Wilcoxon’s rank-sum test. Values are presented as
median (range) unless specified. Statistical calculations were
performed using JMP 7.0, SAS Institute (Cary, NC, USA).
RESULTS
Clinical features of patients with FGN and with MGFD
Of the 2814 KTX performed during this period, 5 patients
had FGN and 7 patients had MGFD as the primary cause for
their native kidney failure. The clinical features at presenta-
tion for the two groups are depicted in Table 1. Six patients
were men and six were women. In patients with FGN, the
median age at diagnosis was 66 (51–67) years, and 56 (29–65)
years for patients with MGFD. The most common clinical
presentations were renal failure and proteinuria. Hyperten-
sion (defined as systolic blood pressure 4140 mm Hg) and
proteinuria were present in all patients. Median proteinuria
was 7.2 (1.9–14.0) g/24 h and nephrotic syndrome was
present in 10 of 12 patients (83%). Median serum creatinine
(SCr) at diagnosis was 2.3 (1.9–2.6) mg/100 ml for patients
with FGN and 1.5 (0.9–2.8) mg/100 ml for patients with
MGFD (P¼ 0.11). Eight patients had hematuria. All patients
were screened for the presence of a monoclonal protein by
serum and urine protein electrophoresis and immunofixation
(or immunoelectrophoresis). Seven patients had a mono-
clonal protein present in the serum (IgG-l, n¼ 4; IgA-l,
n¼ 1; IgA-kþ IgG-k, n¼ 1; monoclonal l, n¼ 1) whereas in
the urine a monoclonal l was present in five patients and
IgA-k in one. With the exception of one patient, monoclonal
proteins have remained present post-KTX in all patients at
last follow-up. In patients with FGN, the median time from
the initial diagnosis to first KTX was 21 (8–63) months. This
time tended to be longer for patients with MGFD, 63
(32–166) months, although this did not reach statistical
significance (P¼ 0.07). The median age at first transplanta-
tion was 67 (range, 53–71) years in patients with FGN and 61
(43–71) for patients with MGFD (P¼ 0.39). The median time
of diagnosis to ESRD was 15 (8–63) months for patients with
FGN and 25 (10–166) months for patients with MGFD
(P¼ 0.17). Two patients with FGN and three patients with
MGFD underwent preemptive KTX. Three of the seven
patients with MGFD underwent a second KTX. No patient
was lost to follow-up.
Native kidney biopsy findings
Light microscopic examination including hematoxylin and
eosin, periodic acid-Schiff, Masson’s trichrome, and Jones
silver stains were available in all cases; IF microscopy was
available in 11 cases and EM in all 12 cases. On light
microscopy, a membranoproliferative pattern was seen in
eight biopsies (67%; FGN¼ 4; MGFD¼ 4) and a membra-
nous nephropathy pattern was seen in one patient with
MGFD. Five biopsy specimens showed secondary focal
segmental or global glomerular sclerosis (FGN¼ 3;
MGFD¼ 2). In all cases, there was some degree of mesangial
matrix expansion from minimal to significant nodular
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sclerosis. The degree of global glomerulosclerosis varied and
ranged from 0 to 53% of the glomeruli. Segmental
glomerulosclerosis was described in a few cases. In three
patients with MGFD, renal biopsy showed crescents. Chronic
interstitial fibrosis was moderate to severe in five cases (45%),
and was usually associated with mild interstitial inflamma-
tion. In patients with FGN, IF microscopy (available in four
of five patients) showed granular IgG/C3 staining, with k and
l equally distributed. In patients with MGFD, linear IgG/C3
with k and l equally distributed was present in three patients,
and granular IgG/C3 with negative k and l in two patients.
One patient had linear to fine granular IgG-l, and one
patient had granular C3, negative IgG, and negative k and l.
On EM, the glomeruli showed mesangial and segmentally
distributed glomerular basement fibrils in all cases, which
were admixed with electron dense material in most cases, and
in a pattern that was indistinguishable between patients with
FGN and MGFD. In patients with FGN, the fibrils diameter
was 19.1±1.4 nm (mean±s.d.) and 17.0±5.7 (mean±s.d.)
in patients with MGFD. In two cases (FGN¼ 1; MGFD¼ 1),
fibrils were also described in tubular basement membranes.
No amyloid fibrils or glomerular or tubular basement
membrane light-chain deposition was identified.
Post-transplant courses
Clinical parameters. Of the 15 KTX episodes, 7 were from
living-related donors (FGN¼ 2; MGFD¼ 5), 3 were from
living-unrelated donors (FGN¼ 1; MGFD¼ 2), and 5 were
from deceased donors (FGN¼ 2; MGFD¼ 3). Immunosup-
pressive regimen included tacrolimus (n¼ 13) or cyclospor-
ine A (n¼ 2), mycophenolate (n¼ 14) or azathioprine
(n¼ 1), and prednisone (n¼ 15; Table 2). In the majority
of patients (n¼ 8), protocol allograft biopsies were per-
formed at 4 months, 1 year, and 2 years post-KTX (Table 3).
In patients with FGN, the median time to allograft failure
could not be determined because Kaplan–Meier survival
estimates never reached 50%. In patients with MGFD, the
median allograft survival was 38 (4–131) months. At the last
follow-up, median SCr in patients with FGN was 1.2
(0.6–1.4) mg/100 ml and 1.3 (0.6–1.8) mg/100 ml in patients
with MGFD (P¼ 0.6; Table 2).
Kidney losses unrelated to recurrent disease. One patient
with FGN (no. 2) who had received a deceased donor KTX in
2001, lost the allograft in the perioperative period because of
acute thromboembolism of the iliac artery resulting in
allograft ischemia requiring subsequent nephrectomy. A later
transplant attempt in 2005 was abandoned because of
Table 1 | Clinical characteristics at diagnosis, treatment, and work-up for lymphoproliferative disorders
No
Age at
diagnosis
(years) Sex
Serum
creatinine at
diagnosis
(mg/100 ml)
Proteinuria
(g/24 h)
Serum
albumin
(g/100 ml) Hematuria
Time from
diagnosis
to
ESRD
(months)
Time from
diagnosis
to
1st KTX
(months)
Paraprotein
Immuno-
suppressive
treatment
before
KTX
Monoclonal protein
workup at diagnosis
Serum Urine
1 51 M 2.5 12.5 2.8 Yes 15 21 — CsA
2 66 F 1.9 6.7 2.1 No 32 62 — None
3 62 M 2.2 1.9 2.8 Yes Preemptive 63 — None
4 67 M 2.6 10.5 2.5 Yes Preemptive 8 — None
5 66 F 2.3 3.4 2.3 Yes 8 12 — None
6 65 F 1.7 4.4 2.2 Yes 10 35 IgG-l — None None
7 56 F 1.5 14 2.9 No 25 63 IgA-l l None BM biopsy: normal;
amyloid=negative
8 45 F 2.8 6.3 2.5 Yes Preemptive 32 IgA-k
IgG-k
IgA-k None BM biopsy: 5% plasma
cells;
amyloid=negative
9 29 F 0.9 7.7 1.5 Yes Preemptive 166 IgG-l l CYC, P BM biopsy: non-
diagnostic
(2-3% plasma cells)
10 63 M 1.4 4 3.7 No Preemptive 88 IgG-l l M, P BM biopsy: atypical
plasma cells (5-10%),
suggestive of early LPD
11 50 M 2.6 9.1 2.9 Yes 25 52 IgG-l l M, P, DEX BM biopsy: 7-10%
Plasma cells
monoclonal IgG-l;
amyloid=negative
12 64 M 1.0 13.1 1.8 No 76 84 l l MMF, P BM biopsy: 5%
plasma cells,
some mildly atypical;
monoclonal l;
amyloid=negative
BM, bone marrow; CsA, cyclosporin A; CYC, cyclophosphamide; DEX, dexamethasone; ESRD, end-stage renal disease; KTX, kidney transplant; LPD, lymphoproliferative
disorder; M, melphalan; MMF, mycophenolic acid; P, prednisone.
Patients 1–5, FGN; patients 6–12, patients with monoclonal gammopathy. Bone marrow biopsies were only performed in patients with positive monoclonal proteins (serum/
urine).
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intercurrent infection. The patient has remained on chronic
hemodialysis for the past 52 months.
One patient with MGFD (no. 6a) who received a deceased
donor KTX lost the allograft after 29 months because of
multiple rejection episodes. This patient underwent a second
deceased donor KTX, 36 months after the first (no. 6b) and
initially had an uneventful course. At 22 months after second
KTX, she presented with hematuria and proteinuria of
1.7 g/24 h (from 46 mg/24 h), and a SCr of 1.0 mg/100 ml.
Allograft biopsy showed evidence for MPGN type III without
fibrillary changes on EM. Proteinuria resolved spontaneously
without changes to her immunosuppressive or antihyperten-
sive regimen and her allograft function remained stable for
the next 90 months (most recent creatinine 1.1 mg/100 ml,
proteinuria of 71 mg/24 h). A previously existing serum
monoclonal IgG-l decreased over the years and is currently
undetectable.
Recurrent disease. None of the patients with FGN had
recurrent disease post-KTX. However, the disease recurred in
five renal allografts in four patients with MGFD, at 3, 13, 24,
25, and 87 months post-KTX. Morphological changes in the
renal allograft biopsies were similar to the ones in the native
kidney biopsies. In one case, recurrence was documented as
early as 3 months (no. 9) after receiving a preemptive living-
related KTX. This patient had developed proteinuria in
August 1987 and underwent a renal biopsy in September
1988 that was reported as FGN. A small monoclonal IgG-l
was found in the serum in March 89 and on occasion, a l-
light chain was also found in the urine. A bone marrow
biopsy was performed that showed no major abnormalities,
but we consider it nondiagnostic in view that no special
stainings of the biopsy nor flow cytometry were performed. A
diagnosis of a monoclonal gammopathy of unknown
significance was made and the patient was followed by
hematology on an annual basis with no changes on
monoclonal protein levels. She received no immunosuppres-
sive therapy until February 2002 when because of progressive
renal failure (SCr, 4.0 mg/100 ml) she was started on
prednisone (6 weeks course) and cyclophosphamide
(4 months course). A repeat renal biopsy performed at the
time of initiation of immunosuppressive therapy showed a
membranoproliferative pattern of glomerulonephritis with
prominent nodularity consistent with the initial diagnosis.
Renal function continued to deteriorate and a preemptive
living-related KTX was performed in October 2002. At 10
days post-KTX, SCr decreased to 1.6 mg/100 ml, but
gradually increased to 2.3 mg/100 ml 3 months post-KTX.
During the same period, proteinuria increased from 1 g/24 h
to 3.6 g/24 h. A renal allograft biopsy showed recurrent
MGFD. In November 2002, a bone marrow biopsy was
performed for anemia work-up that showed 15–20%
involvement by monoclonal plasma cells, with a k–l ratio
of 1:99 (monoclonal l) and a plasma cell labeling index of
1.0% (high 1–3%). Congo red was performed on the biopsy
specimen and was negative. She was diagnosed with a
smoldering myeloma that likely had been present before
KTX. At the time of the diagnosis of myeloma, her SCr had
increased to 2.8 mg/100 ml and proteinuria had increased to
14 g/24 h. She was started on treatment with intermittent
plasmapheresis on the assumption that the circulating
Table 2 | Outcomes of KTX in patients with FGN and in patients with monoclonal gammopathy and fibrillary deposits
No
Age
at KTX Sex Rx ESRD KTX
Follow-up
post-KTX
(mo) Outcome, recurrence time (mo)
1 53 M TAC, MMF, Pred Y LUD 51 Stable allograft function; SCr 1.2 mg/100 ml;
proteinuria 33 mg/24 h
2 71 F TAC, MMF, Pred Y CAD 52 Graft failure, thromboembolism; ESRD o1 month post-KTX
3 67 M TAC, MMF, Pred N LRD 39 Stable allograft function; SCr 1.2 mg/100 ml; proteinuria 80 mg/24 h
4 67 M TAC, MMF, Pred N LRD 61 Stable allograft function; SCr 1.4 mg/100 ml; proteinuria 325 mg/24 h
5 67 F TAC, MMF, Pred Y CAD 39 Stable allograft function; SCr 0.6 mg/100 ml; proteinuria 81 mg/24 h
6a 68 F TAC, AZA, Pred Y CAD 36 Graft failure, multiple rejections; ESRD 29 months post-KTX
6b 71 F TAC, MMF, Pred Y CAD 95 MPGN III 22 months post-KTX; stable allograft function;
SCr 1 mg/100 ml; proteinuria 84 mg/24 h
7 61 F TAC, MMF, Pred Y LRD 4 Died 4 months post-KTX; NHL
8a 48 F CsA, MMF, Pred N LRD 140 Recurrence 87 months post-KTX. ESRD 131 months post-KTX.
Underwent second KTX 135 months after first KTX
8b 59 F TAC, MMF, Pred Y LUD 6 KTX in July 2007; stable allograft function; SCr 0.6 mg/100 ml;
proteinuria 97 mg/24 h
9 43 F TAC, MMF, Pred N LRD 69 Recurrence 3 months post-KTX. Underwent PSCT in January 2005.
SCr 1.7 mg/100 ml; proteinuria 207 mg/24 h
10 71 M TAC, MMF, Pred N LRD 38 Died 38 months post-KTX; leukemia; SCr 1.8 mg/100 ml; proteinuria 39 mg/24 h
11a 54 M CsA, MMF, Pred Y CAD 29 Recurrence 13 months post-KTX; ESRD 29 months post-KTX
11b 59 M TAC, MMF, Pred Y LUD 65 Recurrence 25 months post-KTX; ESRD 35 months post-KTM; CPLD/MM in 2005
12 71 M TAC, MMF, Pred Y LRD 25 Recurrence at 24 months post-KTX; stable allograft function;
SCr 1.3 mg/100 ml; proteinuria 86 mg/24 h
CAD, deceased donor; CPLD/MM, clonal plasma lymphoproliferative disorder/multiple myeloma; CsA, cyclosporine; ESRD, end-stage renal disease; F, female; KTX, kidney
transplant; LRD, living related donor; LUD, living unrelated donor; M, male; MMF, mycophenolic acid; mo, months; N, no; NHL, non-Hodgkin’s lymphoma; pred, prednisone; Rx,
immunosuppressive treatment; SCr, serum creatinine; TAC, tacrolimus; Y, yes.
FGN, 1–5; MGFD, 6–12 () negative; SCr and proteinuria are results at last follow-up.
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monoclonal protein was pathogenic to the kidney and
removal of the paraprotein could be beneficial in preserving
allograft function.21,22 The clinical course initially improved
but was complicated by line-associated Staphylococcus aureus
sepsis with disseminated intravascular coagulation requiring
noninvasive positive pressure ventilation and intermittent
hemodialysis 11 months post-KTX. Dialysis was discontin-
ued 3 months later, but renal function remained impaired
with an SCr of 2.9 mg/100 ml and a creatinine clearance of
16 ml/min. The patient was recommended to undergo
autologous peripheral blood stem cell transplantation
(PBSCT) before considering a new KTX and a PBSCT
was performed on January 2005. Interestingly, following
the PBSCT she recovered allograft function and her SCr
had remained stable at 1.7 mg/100 ml, and proteinuria
is 280 mg/24 h at her last follow-up in June 2008. However,
a small monoclonal IgG-l is still present in serum and
urine.
In another patient with MGFD (no. 11), the disease
recurred twice in two subsequent renal allografts at 13 and 25
months post–transplant, respectively. He reached ESRD 29
and 35 months after KTX and is currently stable on chronic
hemodialysis. A third patient with MGFD (no. 8) was
diagnosed with recurrent FGN 7 years after a preemptive
KTX (no. 8a) in 1996. Progressive renal failure ensued, and
the patient received a second (no. 8b) living-unrelated KTX 4
years after the diagnosis of recurrent disease and 4 months
after initiation of hemodialysis. At last follow-up (6 months),
there is no evidence of recurrent disease with SCr of 0.6 mg/
100 ml and proteinuria 97 mg/24 h. A fourth patient with
Table 3 | Renal allograft biopsies time points
No KTX date Biopsy (LM) IF EM done Recurrence
1 9 September 2003 +1 month Negative 
+4 months Not done 
+1 year C3 1 +; negative k and l  No
+2 years Negative 
2 6 May 2001 t(0) Not done 
3 12 January 2005 +4 months Not done 
+1 year Not done  No
+2 years Negative 
4 1 May 2003 +3 months Not done 
+1 year Negative + No
+2 years Not done 
+ 5 years Negative 
5 15 January 2005 +5 months Not done 
+1.5 years Not done  No
+2 years Not done 
6a 19 November 1996 +4 months Negative + No
+8 months Negative 
6b 3 December 1999 +3 months Not done 
+2 years IgG/A/M 1+, C3 2+, k 1+, l negative + No
+5 years IgG/A/M 1+, C3 2+, k 1+, l 1+ +
7 31 January 2001 +2 weeks Not done +
+2 months Not done  No
+4 months Negative +
8a 28 March 1996 +10 years IgG 1+; negative k and l + Yes
8b 23 July 2007 +3 months Faint IgM; trace k and l + No
9 7 October 2002 +1 month Not done +
+2 months Negative 
+3 months Negative +
+5 months C3 2+; negative k and l + Yes
+10 months C3 2+; negative k and l +
+11 months C3 2+; negative k and l +
+2 years Not done +
+3 years C3 1+; trace k; tubular l 2+ +
10 25 January 2001 +3 months Not done 
+1.5 years Not done  No
11a 6 March 1998 +1 year Granular IgG/C3 1+; negative k and l + Yes
+ 3.5 years Granular IgG; negative k and l +
11b 26 February 2003 +1 month Negative 
+3 months Negative  Yes
+1 year Negative +
+2 years Granular IgG/C3; negative k and l +
12 2 April 2006 +3 months Negative +
+1 year Negative + Yes
+2 years Positive l +
EM, electron microscopy; IF, immunofluorescence; LM, light microscopy; , EM not done; +, EM was done but no fibrils detected; + in bold, time point when fibrils were
detected on EM.
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MGFD (no. 12) has stable allograft function with SCr of
1.3 mg/100 ml and proteinuria 86 mg/24 h at 25 months post-
KTX. However, protocol allograft biopsy at 24 month shows
recurrence of FGN. Of the three allografts lost to the
recurrence, the median time to graft failure was 17 (10–46)
months. In three patients with MGFD (nos. 6, 7, 11), native
kidney biopsies showed a crescentic glomerulonephritis but
crescentic glomerulonephritis did not recur in any of the cases.
Fatal outcomes. Two patients with MGFD died from
lymphoma and leukemia that developed 4 and 38 months
post-KTX, respectively. One patient (no. 10) presented in
September 1993 with nephrotic syndrome, a SCr of 1.4 mg/
100 ml, and a monoclonal IgG-l. On the basis of assumption
that the fibrillary deposits and the nephrotic syndrome were
associated with the underlying plasma cell dyscrasia (smol-
dering myeloma), the patient was treated with melphalan and
prednisone. Kidney function continued to deteriorate, and in
January 2001 the patient underwent a preemptive living-
related KTX. Post-transplant course was complicated by the
development of secondary myelodysplastic syndrome 22
months post-KTX that transformed to acute myelogenous
leukemia (French American British M4) by 35 months post-
KTX. He died 38 months post-KTX because of chemo-
therapy-induced leukemia without evidence of recurrence of
the fibrillary deposits in the allograft at autopsy.
In the other patient, (no. 7) early post-KTX course was
complicated by delayed allograft function requiring dialysis
for 4 weeks. Repeated allograft biopsies confirmed acute
tubular necrosis. Further evaluation during the period of
delayed allograft function revealed significant stenosis of the
iliac artery proximal to the anastomosis of the renal allograft.
This was treated with percutaneous transluminal angioplasty
that resulted in resolution of the graft dysfunction, and her
SCr decreased to 1.3 mg/100 ml. At 4 months after KTX, the
patient was admitted to the hospital with acute renal failure
(SCr 3.4 mg/100 ml), fever, dehydration, a hemoglobin level
of 6.5 g/100 ml, and total white cell count of 1.1 103/ml. She
was diagnosed with a post-transplant lymphoproliferative
disorder involving the renal allograft and her bone marrow.
In situ hybridization, studies were performed on the biopsy
specimen using probes that recognize Epstein–Barr virus
messenger RNA. Numerous Epstein–Barr virus-positive cells
were identified within the foci of lymphoproliferative
disorder using this technique. These findings support the
diagnosis of a post-transplant lymphoproliferative disorder.
She died on hospital day 17 despite multimodal therapy.
DISCUSSION
Fibrillary glomerulonephritis is a glomerular disease first
reported in 1977 by Rosenmann and Eliakim23. Because of its
rarity, little is known about post-KTX outcomes in FGN.
Only a small number of patients with FGN and KTX have
been reported.4,7,16,17 In the largest review of KTX in patients
with FGN, biopsy-proven recurrent disease occurred in
42.8%.17 In one patient, FGN recurred twice.7 As suggested
by the authors, it is possible that the recurrence rate was
underestimated as no biopsy was performed in 6 of the 14
patients. During the post-KTX follow-up period that ranged
from 2 to 13 years (mean 6.4±3.0 years), only 3 patients lost
their graft because of recurrent disease.7,16,17 One patient
(not biopsied) died with normal graft function 7 years post-
KTX, and four patients had adequate graft function in spite of
biopsy-proven recurrent FGN 2–11 years post-KTX.6,7,17 In six
patients who did not undergo allograft biopsies, normal renal
function was maintained up to 8 years post-KTX. According to
this series, the nature of the recurrent disease was reportedly
benign and associated with prolonged graft survival.17 More
recently, Rosenstock et al.4 reported the largest single center
series of 61 cases of FGN. Two patients received a cadaveric
KTX. One patient had no clinical evidence of recurrence after 8
years, with normal SCr and no proteinuria. The other patient
died 4 years after KTX because of colon cancer with a stable
SCr of 2.2 mg/100 ml at the time of death. Because of stable
allograft function and absence of proteinuria, neither of the
patients underwent allograft biopsy.
From the literature, it is difficult to estimate the time to
recurrence of FGN, for timing of the allograft biopsy is
provided only for four patients. Korbet et al.16 described a
patient who underwent allograft biopsy 21 months post-KTX
that did not show recurrent disease, but a subsequent biopsy
performed 52 months post-KTX showed characteristic fibrils
(22.5 nm in diameter) and the patient lost the graft 4 months
later because of recurrent disease. The patient reported by
Alpers et al.6 with recurrent FGN had a very short follow-up
time after the biopsy, which was obtained 5 years post-KTX.
In their own four cases, Samaniego et al.17 documented
biopsy-proven recurrent FGN in two patients at 2 and 9 years
post-KTX. Similarly, donor information is available in only
eight patients.4,16,17 FGN recurred in three of four patients
who underwent living-related KTX, although there was no
apparent recurrence in four KTX from deceased donors.4,17
Our experience with patients with FGN correlates well
with the published literature. With the except for one patient
who lost the allograft 1 week after KTX from an iliac artery
thromboembolism, the other four patients with FGN have
stable renal function 45 (39–61) months after KTX, and no
evidence of recurrence.
The same claim could not be made for patients with
MGFD. In these patients, KTX was associated with significant
complications developing in seven (58.3%) patients. Disease
recurrence was observed in five allografts in four separate
patients, with recurrence resulting in graft loss in three
instances. In these patients, recurrence occurred as early as 3
months and as late as 7 years post-KTX. In one patient (no.
4), protocol biopsy documented recurrence as early as 1 year
after first KTX and at 2 years after second KTX. In both
instances, proteinuria was mild: 340 mg/24 h and 271 mg/
24 h. Similarly, protocol biopsy documented recurrence at 2
years post-KTX in a patient (no. 12) with stable allograft
function and no proteinuria. The early diagnosis of
recurrence in these patients is likely because of the use of
protocol biopsies in our program that has resulted in
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histologic diagnosis before clinical manifestations in a
number of cases.24 Although the number of cases is small,
recurrence did not appear to be related to kidney donor and
occurred in two of five (40%) of living-related KTX, in one of
two (50%) living unrelated KTX, and in one (33%) of three
deceased donor KTX. Two patients died from a hematologic
malignancy without disease recurrence: the first from a
chemotherapy-related leukemia and the second from a post-
transplant lymphoproliferative disorder. Another patient (no.
6b), whose preexisting monoclonal gammopathy sponta-
neously disappeared, developed MPGN type III without
evidence of fibrillary deposits in the kidney.
As discussed in the introduction, a number of cases of
fibrillary glomerular deposits have been described in patients
with a monoclonal gammopathy of unknown significance.18–21
Monoclonal gammopathy of unknown significance is defined
as a serum monoclonal protein less than 3.0 g/100 ml; less than
10% plasma cells in the bone marrow, if done; little or no
monoclonal protein in the urine; and absence of lytic bone
lesions, anemia, hypercalcemia, or renal insufficiency.25 It has
been reported in approximately 1% of people older than 50
years and in about 3% of those older than 70 years.26 It
produces no symptoms and is found during laboratory testing
of an apparently normal patient or during evaluation of an
unrelated disorder. Long-term follow-up studies show that
multiple myeloma, amyloidosis, Waldenstro¨m macroglobuli-
nemia, or a related malignant lymphoproliferative disorder will
develop in 17% of patients at 10 years, 34% at 20 years, and
39% at 25 years, a rate of approximately 1.5% per year.27 We
believe however that in patients with MGFD, the monoclonal
proteins should not be called of ‘unknown significance’. In fact,
the present data strongly suggests that in these patients the
circulating monoclonal proteins are pathogenic and support
the hypothesis raised by Korbet et al.,28 of a connection
between the monoclonal gammopathy and the nature of the
renal deposits. Our experience is similar in patients with
membranoproliferative glomerulonephritis and a monoclonal
gammopathy where we have observed a high rate of recurrent
disease post-KTX.
The present study represents the largest single-center case
series of post-KTX outcomes in patients with FGN and
MGFD, with 15 KTX episodes in 12 patients. In this limited
number of patients with FGN no recurrence was observed.
Moreover, in patients with MGFD, KTX was highly
associated with significant post-transplant complications
including graft loss from recurrence and death from
hematologic malignancies. Our results suggest that the
patients with MGFD represent a high-risk population for
both patient and allograft after KTX. We have described a
similar experience in patients with monoclonal immunoglo-
bulin deposition disease who underwent KTX.29,30 However,
recurrence was not inevitably associated with graft loss in our
series, since 1 patient who underwent PBSCT for her
myeloma was able to recover and stabilize allograft function.
In patients with MGFD, the increased incidence of hemato-
logical malignancies diagnosed soon after KTX suggests that
these patients should undergo a thorough hematological
work-up, before clearance for transplantation.
In summary, KTX appears a viable therapeutic option for
patients with ESRD secondary to FGN. However, in patients
with MGFD, the reduced allograft and patient survival make
KTX in these patients controversial especially in patients with
a persistent monoclonal gammopathy. We suggest that KTX
should be performed primarily on those patients who have
attained remission of the hematological dyscrasia or who are
candidates to receive aggressive therapy capable of achieving
remission (e.g. PBSCT). Further studies to facilitate the
understanding of recurrence and its prevention are needed
before KTX can be offered as a standard treatment for
patients with MGFD who developed ESRD.
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